May 24 (Reuters) - PDL Biopharma Inc
* Transaction expected to be immediately accretive
* PDL expects to make equity contributions to Noden totaling approximately $107 million in first year of transaction
* Noden is also expected to obtain debt financing in conjunction with PDL equity investment.
* PDL will have three of five seats on Noden’s board of directors
* PDL Biopharma commits to equity investment in Noden Pharma for the acquisition of Tekturna (aliskiren) and Tekturna HCT (aliskiren and hydrochlorothiazide) Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)